Rankings
▼
Calendar
DNLI Q1 2020 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena
DNLI
Denali Therapeutics Inc.
$3B
Q1 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$4M
-14.3% YoY
Gross Profit
$4M
100.0% margin
Operating Income
-$60M
-1663.9% margin
Net Income
-$57M
-1575.0% margin
EPS (Diluted)
$-0.55
QoQ Revenue Growth
-22.9%
Cash Flow
Operating Cash Flow
-$54M
Free Cash Flow
-$55M
Stock-Based Comp.
$11M
Balance Sheet
Total Assets
$696M
Total Liabilities
$151M
Stockholders' Equity
$545M
Cash & Equivalents
$208M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$4M
$4M
-14.3%
Gross Profit
$4M
$4M
-14.3%
Operating Income
-$60M
-$43M
-41.1%
Net Income
-$57M
-$39M
-45.6%
Revenue Segments
Alzheimer's Disease Services
$3M
100%
← FY 2020
All Quarters
Q2 2020 →